Soluble Interleukin-2 Receptor As A Disease Indicator And A Method Of Assaying The Same
Description of Invention:
Soluble IL-2 receptor is produced in response to immune activation and by some malignant cells. For instance, elevated levels of IL-2 have been detected in patients with adult T-cell leukemia, Sezary syndrome, Hodgkin's disease, chronic lymphocytic leukemia, multiple myeloma, and solid tumors. The systemic level of IL-2 receptor is also relevant in the diagnosis and treatment of such diseases as rheumatoid arthritis and systemic lupus erythematosis and may be used to titrate immunosuppressive therapy in such applications as graft rejection.
The invention disclosed in the patent is a sandwich immunoassay useful for determining the amount of IL-2 receptor in a sample. The invention also discloses a method of detecting such disturbed or abnormal conditions in humans which release soluble IL-2 receptor in bodily fluids.
Inventors:
D Nelson W Biddison L Rubin W Greene W Leonard R Yarchoan (NCI)
Patent Status:
DHHS Reference No. E-213-1985/0 Licensing Status: This technology is no longer available for licensing.
Portfolios: Internal Medicine Cancer
Cancer -Therapeutics-Biological Response Modifiers Internal Medicine-Diagnostics-Anti-Inflammatory (including Autoimmune) Internal Medicine-Therapeutics-Anti-Inflammatory (including Autoimmune) Cancer -Diagnostics Cancer -Therapeutics Internal Medicine-Diagnostics Internal Medicine-Therapeutics
For Additional Information Please Contact: Mojdeh Bahar J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-2950
Email: baharm@mail.nih.gov
Fax: (301) 402-0220
